Bio-IT World May 25, 2022
$381M: New Fund for Biomedical Technology
Catalio Capital Management announced the successful close of its third venture fund, Catalio Nexus Fund III (“Fund III” or the “Fund”), with more than $381 million in total capital commitments, exceeding its original 300-million-dollar target. In addition, the Fund received significant backing from current Catalio investors and several new global institutional investors, foundations, and endowments. Consistent with the successful approach of its predecessor vehicles, Fund III will invest in breakthrough biomedical technology companies at all stages of growth, from inception to IPO.
$147.5M: Series B Funding for Parkinson’s Disease Therapy
Aspen Neuroscience, a private biotechnology company developing autologous cell therapies, including the first iPSC-derived...
Today's Sponsors
Today's Sponsor